Pure Global
NCT06310304

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Relative Bioavailability of Ruxolitinib XR Tablets Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
Incyte Corporation·Phase 1·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
Ruxolitinib IR
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Incyte Corporation
Location
Lincoln, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Mar 26, 2024
End date
May 15, 2024
Enrollment
24 participants
Primary outcome

INCB018424 pharmacokinetic (PK) in Plasma

Summary

This study is conducted to determine the Relative Bioavailability of Ruxolitinib XR Tablets
 Compared With Ruxolitinib IR Tablets Administered Orally in Healthy Participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06310304
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06310304 through Pure Global AI's free database. This Phase 1 trial is sponsored by Incyte Corporation and is currently Recruitment Completed. The study focuses on Healthy Participants. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.